Skip to main content
New Pill Doubles Pancreatic Cancer Survival
Lead Story
Health 15 minutes ago

New Pill Doubles Pancreatic Cancer Survival

A groundbreaking new pill, daraxonrasib, has demonstrated remarkable success in clinical trials for metastatic pancreatic cancer, effectively doubling patients' median survival time from 6.7 to 13.2 months. This significant breakthrough offers renewed hope by targeting specific cancer cell pathways, providing a much-needed therapeutic option for a previously intractable disease.

A groundbreaking new pill, daraxonrasib, has demonstrated remarkable success in clinical trials for metastatic pancreatic cancer, effectively doubling patients' median survival time from 6.

Catamist Editorial
News Desk

Latest updates

More Articles

Accessibility Options

Font Size

100%

High Contrast

Reading Preferences

Data & Privacy